Clinical Trials
3 trialsNCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT05465343 2025-12-19
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Peking Union Medical College
Phase 2 Completed
NCT04671303 2025-05-11
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed